The LCMC3 study showed that neoadjuvant atezolizumab was well tolerated and met its primary endpoint, achieving a major pathologic response rate of 21% in patients without EGFR/ALK mutations. The therapy also showed high complete resection rates and low perioperative morbidity and mortality.
A study at Boston Children's Hospital found that a multidisciplinary ERAS program reduced opioid use, improved pain control, and expedited recovery for select congenital heart surgery patients. The program implemented strategies like early extubation, blood conservation, and smaller surgical incisions to enhance patient outcomes.
Researchers at Nagoya University have discovered two types of fibroblasts, meflin and gremlin 1, that play a crucial role in regulating colorectal cancer progression. Altering the balance between these cells could be an effective strategy for preventing cancer progression.
A host immune classifier test may help guide immunotherapy treatment decisions for patients with newly diagnosed non-small cell lung cancer. The test, which measures inflammation in the body, is associated with longer overall survival and better treatment response.
Researchers analyzed mRNA expression levels of molecular markers ERCC1 and thymidylate synthase in patients with resected stage II-III non-small cell lung cancer. The study found no correlation between these markers and overall survival, contradicting previous hopes for a personalized chemotherapy approach.
A recent study found a 53% decrease in adult cardiac surgery volume nationwide, with a 65% reduction in elective cases. The pandemic also led to an unexplained increase in deaths after coronary artery bypass grafting, with significant declines in case volume and patient outcomes.
A nationwide lung cancer LDCT screening study found the effectiveness of low-dose computed tomography (LDCT) screening in a pre-defined, never-smoker population. The study revealed that family history significantly increased lung cancer risk, and most participants had stage 0 or 1 disease.
A recent study has found that women are less likely to receive guideline-recommended approaches for coronary artery bypass grafting (CABG), resulting in worse outcomes. This disparity may be attributed to delayed diagnosis of heart disease, which leads to undertreatment and poorer surgical results.
The Checkpoint Blockade for Inhibition of Relapsed Mesothelioma (CONFIRM) study demonstrated that nivolumab significantly improves overall and progression-free survival in patients with relapsed malignant mesothelioma. The treatment also showed a consistent safety profile without new adverse effects.